<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01697020</url>
  </required_header>
  <id_info>
    <org_study_id>INV298</org_study_id>
    <nct_id>NCT01697020</nct_id>
  </id_info>
  <brief_title>Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions</brief_title>
  <official_title>A SINGLE CENTER, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, TWO-PERIOD CROSSOVER STUDY TO ASSESS THE BIOEQUIVALENCE OF AN ORAL MERCAPTOPURINE SUSPENSION 100 mg / 5 mL VERSUS AN ORAL MERCAPTOPURINE TABLET 50 mg (PURINETHOL®) IN AT LEAST 62 HEALTHY MALE SUBJECTS UNDER FASTING CONDITIONS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Laboratories Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether the test product, mercaptopurine&#xD;
      oral 100 mg/5 mL suspension, and the reference product, Purinethol® 50 mg tablets are&#xD;
      bioequivalent. For this purpose the PK profile of 6-mercaptopurine (6-MP) will be compared&#xD;
      after administration of a single dose of each of the two formulations, under fasting&#xD;
      conditions. The secondary objective is to assess the safety and tolerability of the test&#xD;
      product, mercaptopurine oral 100 mg/5 mL suspension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
    <time_frame>Within 7 days</time_frame>
    <description>At each treatment period, pharmacokinetic blood samples will be collected through the indwelling venous cannula at the following times: pre-dose and post-dose at 0.17, 0.33, 0.5, 0.75, 1.0, 1.33, 1.67, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10.0 and 12.0 hours.&#xD;
The primary outcome measures will be&#xD;
Maximum observed plasma concentration (Cmax).&#xD;
AUC time zero to time of the last quantifiable concentration (AUC(0-t))&#xD;
Area under the plasma concentration versus time data pairs, with extrapolation to infinity (AUC(0-∞)).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mercaptopurine 20mg/ml Oral Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mercaptopurine 50mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine 20mg/ml oral suspension</intervention_name>
    <description>50mg</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Xaluprine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine 50mg tablet</intervention_name>
    <description>50mg</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Purinethol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects, 18 years to 50 years inclusive at time of last administration&#xD;
             of the IMP.&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18.5 and 30 kg/m2.&#xD;
&#xD;
          -  Body mass not less than 50 kg.&#xD;
&#xD;
          -  Medical history, physical examination, standard 12-lead electrocardiogram (ECG) and&#xD;
             laboratory investigations: Findings clinically acceptable or within laboratory&#xD;
             reference ranges for the relevant laboratory tests, unless the investigator considers&#xD;
             the deviation to be irrelevant for the purpose of the study.&#xD;
&#xD;
          -  Non-smokers.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current alcohol use &gt; 21 units of alcohol per week for males.&#xD;
&#xD;
          -  Regular exposure to substances of abuse (other than alcohol) within the past year.&#xD;
&#xD;
          -  Use of any medication, prescribed or over-the-counter or herbal remedies, within 2&#xD;
             weeks prior to the first administration of IMP except if this will not affect the&#xD;
             outcome of the study in the opinion of the investigator.&#xD;
&#xD;
          -  Participation in another study with an experimental drug, where the last&#xD;
             administration of the previous IMP was within 8 weeks before the first administration&#xD;
             of IMP in this study.&#xD;
&#xD;
          -  Treatment within the previous 3 months before the first administration of IMP with any&#xD;
             drug with a well-defined potential for adversely affecting a major organ or system.&#xD;
&#xD;
          -  A major illness during the 3 months before commencement of the screening period.&#xD;
&#xD;
          -  Subjects with a deficient, low or intermediate TPMT enzyme activity by means of&#xD;
             phenotyping.&#xD;
&#xD;
          -  Subjects who participated in previous azathioprine/mercaptopurine studies within six&#xD;
             months will be excluded.&#xD;
&#xD;
          -  Relevant history or laboratory or clinical findings indicative of acute or chronic&#xD;
             disease, likely to influence study outcome.&#xD;
&#xD;
          -  Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the&#xD;
             first administration of IMP.&#xD;
&#xD;
          -  Diagnosis of hypotension or hypertension made during the screening period or current&#xD;
             diagnosis of hypertension.&#xD;
&#xD;
          -  Resting pulse of &gt; 100 beats per minute or &lt; 45 beats per minute during the screening&#xD;
             period, either supine or standing.&#xD;
&#xD;
          -  Positive testing for HIV and/or Hepatitis B and/or Hepatitis C.&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse.&#xD;
&#xD;
          -  Positive urine screen for tobacco use.&#xD;
&#xD;
          -  Subjects who plan to procreate within 12 weeks after IMP administration, or not&#xD;
             willing to practice reliable forms of contraception during the study and for at least&#xD;
             12 weeks after the last dose of IMP.&#xD;
&#xD;
          -  Immunization using a live organism vaccine within 4 weeks prior to the first dosing of&#xD;
             IMP.&#xD;
&#xD;
          -  Any specific IMP safety concern.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Parexel International, Bloemfontein Early Phase Clinical Unit</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>September 20, 2012</study_first_submitted>
  <study_first_submitted_qc>September 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2012</study_first_posted>
  <last_update_submitted>November 28, 2013</last_update_submitted>
  <last_update_submitted_qc>November 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mercaptopurine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 3, 2020</submitted>
    <returned>April 15, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

